Personalized peptide vaccines and their relation to other therapies in urological cancer
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Urology"
DOI: 10.1038/nrurol.2017.77
Abstract: Immunotherapy is an important therapeutic modality for urological cancers and several immunological agents for their treatment, such as sipuleucel-T and immune checkpoint inhibitors, have been approved by the FDA. Personalized peptide vaccines (PPVs) are an… read more here.
Keywords: personalized peptide; peptide vaccines; vaccines relation; urological cancers ... See more keywords
Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Science"
DOI: 10.1111/cas.13404
Abstract: This study investigated the applicability of personalized peptide vaccination (PPV) for patients with metastatic upper tract urothelial cancer (mUTUC) after failure of platinum‐based chemotherapy. In this single arm, open‐label, phase II clinical trial, patients with… read more here.
Keywords: personalized peptide; upper tract; metastatic upper; treatment ... See more keywords
Personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel chemotherapy: A randomized, double-blind, placebo-controlled, phase III trial.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.5033
Abstract: 5033 Background: To develop a new treatment modality, we conducted a phase III randomized trial of personalized peptide vaccination (PPV) for human leukocyte antigen (HLA) -A24 positive patients with castration-resistant prostate cancer (CRPC) who failed… read more here.
Keywords: phase iii; placebo; personalized peptide; docetaxel chemotherapy ... See more keywords